Despite the tough market conditions for the industry over the past 2–3 years, the biotechnology sector is poised for big things moving forward. Exciting advances in precision genome editing, cell therapy, synthetic biology, organs-on-chips, next-gen sequencing and artificial intelligence all bode well for the development of new therapies and the health of patients and the industry.

In The State of Biotech 2023–sponsored exclusively by Cytiva–GEN proudly brings together a host of luminaries from industry and academia to discuss the latest research developments, innovations and disruptive technologies that will spur biotech forward to bigger and better things.

Please join us on September 13 for an exciting program featuring:

• Opening keynote conversation with 2022 Nobel laureate Carolyn Bertozzi, PhD
• A keynote presentation from David Baker, PhD (University of Washington/HHMI)
• Panel discussions on the state of CRISPR/genome editing and cell therapy
• Roundtables on the state of synbio and mRNA therapeutics
• A conversation on biotech business trends with the four co-hosts of the popular Biotech Hangout show
• Breakout sessions and much more

The State of Biotech 2023 is GEN’s flagship virtual event, following its successful introduction in 2022. Registration is entirely free.

Supported by

Cytiva joins in supporting the mission of RFS in advancing women and minorities in science.